Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2023; 11(11): 2528-2534
Published online Apr 16, 2023. doi: 10.12998/wjcc.v11.i11.2528
Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
Qian Zou, Rui-Lin Shen, Xiao Guo, Chen-Ye Tang
Qian Zou, Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China
Rui-Lin Shen, Xiao Guo, Chen-Ye Tang, Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314001, Zhejiang Province, China
Author contributions: Tang CY conceived the idea; Zou Q collected data and drafted the manuscript; Shen RL and Guo X have reviewed the manuscript; All authors read and approved the final draft of the manuscript.
Supported by Jiaxing Science and Technology Foundation, No. 2021AY30018.
Informed consent statement: Written informed consent was obtained from all the patients.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chen-Ye Tang, Doctor, Department of Urology, The Second Affiliated Hospital of Jiaxing University, No. 1518 Huancheng Bei Lu, Nanhu District, Jiaxing 314001, Zhejiang Province, China. john99233@126.com
Received: December 21, 2022
Peer-review started: December 21, 2022
First decision: January 20, 2023
Revised: February 1, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: April 16, 2023
Processing time: 105 Days and 20.5 Hours
Abstract
BACKGROUND

Prostate cancer (PC) is currently the most common malignant tumor of the genitourinary system in men. Radical prostatectomy (RP) is recommended for the treatment of patients with localized PC. Adjuvant hormonal therapy (AHT) can be administered postoperatively in patients with high-risk or locally advanced PC. Chemotherapy is a vital remedy for castration-resistant prostate cancer (CRPC), and may also benefit patients with PC who have not progressed to CRPC.

CASE SUMMARY

A 68-year-old male was admitted to our hospital because of urinary irritation and dysuria with increased prostate-specific antigen (PSA) levels. After detailed examination, he was diagnosed with PC and treated with laparoscopic RP on August 3, 2020. AHT using androgen deprivation therapy (ADT) was performed postoperatively because of the positive surgical margin, extracapsular extension, and neural invasion but lasted only 6 mo. Unfortunately, he was diagnosed with rectal cancer about half a year after self-cessation of AHT, and was then treated with laparoscopic radical rectal resection and adjuvant chemotherapy using the capecitabine plus oxaliplatin (CapeOx) regimen. During the entire treatment process, the patient's PSA level first declined significantly after treatment of PC with laparoscopic RP and ADT, then rebounded because of self-cessation of ADT, and finally decreased again after CapeOx chemotherapy.

CONCLUSION

CapeOx chemotherapy can reduce PSA levels in patients with high-risk locally advanced PC, indicating that CapeOx may be an alternative chemotherapy regimen for PC.

Keywords: Prostate cancer; Chemotherapy; Prostate-specific antigen; Rectal tumor; Androgen deprivation therapy; Case report

Core Tip: Chemotherapy is mainly used for castration-resistant prostate cancer (PC) (CRPC) and may also benefit patients with PC who have not progressed to CRPC. We describe a patient with high-risk locally advanced PC treated with laparoscopic radical prostatectomy plus short-term adjuvant hormonal therapy and rectal cancer treated with laparoscopic radical rectal resection plus adjuvant chemotherapy, and found that prostate-specific antigen declined after the capecitabine plus oxaliplatin chemotherapy.